New tetanus antibody could replace Blood-Derived treatments

NCT ID NCT06939777

Completed Disease control Sponsor: Sinovac Life Sciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1/2 trial tested a new lab-made antibody called SNA02-48 for treating tetanus in 255 Chinese adults. The study compared SNA02-48 to the standard treatment (human tetanus immunoglobulin) to see if it is safe and how well it works. The goal is to find a more reliable and potentially safer option for preventing tetanus infection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SNA02-48 (a lab-made antibody against tetanus toxin)
What this could lead to: If successful, this could offer a new, safer alternative to current tetanus treatments derived from human blood.
What could go wrong: This is an early-phase trial (Phase 1/2) with only 255 participants, so results may not confirm effectiveness or safety in larger populations. The antibody may not work as well as existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TETANUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tetanus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TETANUS

Contacts and locations

Locations

The Second Hospital of Anhui Medical Universiy

Hefei, Anhui, 230601, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.